{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:38:38Z","timestamp":1791308318809,"version":"4.3.1"},"reference-count":145,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian cancer remains the most lethal gynecologic malignancy, with immune evasion a major driver of therapeutic resistance and disease progression. Among novel targets, the immune checkpoint molecules B7-H3 and B7-H4 have been recognized for their potent immunosuppressive roles and selective overexpression in ovarian tumors. This review examines the immunological mechanisms shaping B7-H3 and B7-H4 activity within the ovarian tumor microenvironment, their role in facilitating immune escape, and their association with poor clinical outcomes. The development of antibody\u2013drug conjugates targeting B7-H3 and B7-H4 offers a novel approach to deliver potent cytotoxic therapy with tumor specificity. Preclinical models and early-phase clinical studies demonstrate encouraging antitumor activity, including in treatment-resistant disease. By integrating advances in tumor immunobiology and ADC technology, this review explores how targeting B7-H3 and B7-H4 could reshape therapeutic strategies in ovarian cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1683674","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:22:26Z","timestamp":1763619746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Emily Frances","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Kasherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102074","DOI":"10.1016\/j.canep.2021.102074","article-title":"Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study","volume":"76","author":"Gaitskell","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"B2","unstructured":"Ovarian cancer \u2014 Cancer stat facts\n          \n          2024"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.3390\/diagnostics13223484","article-title":"Prognosis following surgery for recurrent ovarian cancer and diagnostic criteria predictive of cytoreduction success: A systematic review and meta-analysis","volume":"13","author":"Gaba","year":"2023","journal-title":"Diagnostics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008765.pub3","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2013","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: A review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/jcm14020470","article-title":"Prognostic factors after the first recurrence of ovarian cancer","volume":"14","author":"Salas Bol\u00edvar","year":"2025","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.08.013","article-title":"New approaches for targeting platinum-resistant ovarian cancer","volume":"77","author":"McMullen","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/cancers10090302","article-title":"Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment","volume":"10","author":"Drakes","year":"2018","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.05.010","article-title":"Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary","volume":"162","author":"Sue-A-Quan","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"TPS5598","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5598","article-title":"DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients","volume":"37","author":"Harter","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"TPS5603","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5603","article-title":"ENGOT-OV43\/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer","volume":"37","author":"Vergote","year":"2019","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5506","article-title":"FIRST\/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC)","volume":"43","author":"Hardy-Bessard","year":"2025","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6005","article-title":"Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer","volume":"38","author":"Matulonis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5515","article-title":"A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512)","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5565","article-title":"A multicenter phase II randomized trial of durvalumab (D) versus physician\u2019s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3)","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2022.00077","article-title":"Advancing antibody-drug conjugates in gynecological Malignancies: myth or reality","volume":"3","author":"Nerone","year":"2022","journal-title":"Explor Target Anti-Tumor Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res MCR"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.01.018","article-title":"The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation","volume":"306","author":"Salceda","year":"2005","journal-title":"Exp Cell Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2\u2013CCR2\u2013M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.02.007","article-title":"Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside","volume":"11","author":"Luo","year":"2025","journal-title":"Trends Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.08.017","article-title":"A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer","volume":"127","author":"Fauci","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692360","article-title":"Shaping immune responses in the tumor microenvironment of ovarian cancer","volume":"12","author":"Luo","year":"2021","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"102936","DOI":"10.1016\/j.esmoop.2024.102936","article-title":"Targeting the immune microenvironment in ovarian cancer therapy\u2014mission impossible","volume":"9","author":"Blanc-Durand","year":"2024","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"10859","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.13","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we go from here","volume":"6","author":"Yoon","year":"2023","journal-title":"Cancer Drug Resist Alhambra Calif"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-response association of CD8+ Tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"189017","DOI":"10.1016\/j.bbcan.2023.189017","article-title":"Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond","volume":"1878","author":"Wu","year":"2023","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00104","article-title":"The role of the tumor stroma in ovarian cancer","volume":"4","author":"Davidson","year":"2014","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.026","article-title":"LBA30 Phase III ATALANTE\/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)","volume":"33","author":"Kurtz","year":"2022","journal-title":"Ann Oncol"},{"key":"B44","unstructured":"Merck announces phase 3 KEYNOTE-B96 trial met primary endpoint of progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3390\/biomedicines10112826","article-title":"The role of TIM-3 and LAG-3 in the microenvironment and immunotherapy of ovarian cancer","volume":"10","author":"Koz\u0142owski","year":"2022","journal-title":"Biomedicines"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412328","article-title":"Recent advances in understanding the immune microenvironment in ovarian cancer","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.600238","article-title":"The expression of three negative co-stimulatory B7 family molecules in small cell lung cancer and their effect on prognosis","volume":"11","author":"Qiu","year":"2021","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.03.553","article-title":"B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look","volume":"134","author":"Smith","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer \u2013 beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00755-06","article-title":"Generation and characterization of B7-H4\/B7S1\/B7x-deficient mice","volume":"26","author":"Suh","year":"2006","journal-title":"Mol Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1293-6","article-title":"The expression, function, and clinical relevance of B7 family members in cancer","volume":"61","author":"Seliger","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s40425-019-0816-5","article-title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","volume":"7","author":"MacGregor","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2016.06.011","article-title":"B7-H4 expression in ovarian serous carcinoma: a study of 306 cases","volume":"57","author":"Liang","year":"2016","journal-title":"Hum Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S222224","article-title":"B7-H3 induces ovarian cancer drugs resistance through an PI3K\/AKT\/BCL-2 signaling pathway","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4301","article-title":"Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer","volume":"11","author":"Xu","year":"2016","journal-title":"Oncol Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839028","article-title":"B7-H3 is a potent inhibitor of human T cell activation: No evidence for B7-H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur J Immunol"},{"key":"B60","article-title":"Research progress of B7-H3 in Malignant tumors","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S521008","article-title":"Preclinical evaluation of a B7-H3 targeting antibody enhancing NK cell-mediated cytotoxicity for ovarian cancer treatment","volume":"14","author":"Hagelstein","year":"2025","journal-title":"ImmunoTargets Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","article-title":"mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1866","article-title":"Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma","volume":"67","author":"Kryczek","year":"2007","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3457","article-title":"Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses","volume":"73","author":"Dangaj","year":"2013","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"140767","DOI":"10.1016\/j.ijbiomac.2025.140767","article-title":"A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective","volume":"304","author":"Zhao","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"mAbs"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c21-00258","article-title":"Recent advances in drug-antibody ratio determination of antibody-drug conjugates","volume":"69","author":"Matsuda","year":"2021","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"B78","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1208\/s12248-019-0390-2","article-title":"A systems pharmacology model for drug delivery to solid tumors by antibody-drug conjugates: implications for bystander effects","volume":"22","author":"Burton","year":"2019","journal-title":"AAPS J"},{"key":"B79","unstructured":"FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer\n          \n          2021"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B81","unstructured":"FDA approves mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer\n          \n          2024"},{"key":"B82","unstructured":"Vobra duo (B7-H3 ADC) \u2013 macroGenics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","article-title":"Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"39","author":"Jang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B84","article-title":"1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)","volume":"34","author":"Bono","year":"2023","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-330","article-title":"Abstract 330: Targeting B7-H3 in prostate cancer: Preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate","volume":"82","author":"Scribner","year":"2022","journal-title":"Cancer Res"},{"key":"B87","unstructured":"MGC026 (B7-H3 ADC) \u2013 macroGenics"},{"key":"B88","article-title":"Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) Targeting B7-H3 for Solid Cancer","author":"Scribner","year":"2024"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1158\/1538-7445.AM2023-4891","article-title":"Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization","volume":"83","author":"Katsumata","year":"2023","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS -8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B92","unstructured":"DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.582","article-title":"453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I\/II study","volume":"33","author":"Doi","year":"2022","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS847","article-title":"A phase 1 dose escalation\/expansion study of GSK5764227 (GSK\u2019227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers","volume":"43","author":"Saif","year":"2025","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3017","article-title":"ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced solid tumor","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B96","unstructured":"FDA grants breakthrough therapy designation to GSK\u2019s GSK5764227 for relapsed or refractory extensive-stage small-cell lung cancer\n          \n          2024"},{"key":"B97","unstructured":"FDA grants breakthrough therapy designation to GSK\u2019227 to treat osteosarcoma\n          \n          2025"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT165","article-title":"Abstract CT165: A phase 1\/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced\/metastatic solid tumors","volume":"84","author":"Cheng","year":"2024","journal-title":"Cancer Res"},{"key":"B99","unstructured":"FDA Grants Fast Track Designation to BNT324\/DB-1311 in mCRPC\n          \n          2024"},{"key":"B100","unstructured":"Minghui Pharmaceutical Presents Phase 1\/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3012","article-title":"Results of a phase 1\/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B102","unstructured":"Definition of anti-B7-H3 antibody-drug conjugate BAT8009 - NCI Drug Dictionary - NCI\n          \n          2011"},{"key":"B103","unstructured":"Bio-thera solutions announces first patient dosed in phase 1 study for BAT8009, an antibody drug conjugate targeting B7-H3 (CD276) for the treatment of advanced solid tumors"},{"key":"B104","unstructured":"FDA grants orphan drug designation to 7MW3711"},{"key":"B105","unstructured":"Mabwell receives IND approval from FDA for novel B7-H3 ADC 7MW3711\n          \n          2024"},{"key":"B106","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12935-023-02991-x","article-title":"ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors","volume":"23","author":"Shin","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","article-title":"Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose expansion results","volume":"41","author":"Carneiro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B108","unstructured":"Definition of mirzotamab clezutoclax - NCI Drug Dictionary - NCI\n          \n          2011"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae165.0525","article-title":"DDDR-40. TARGETING BCL-XL WITH MIRZOTAMAB CLETUZOCLAX (ABBV-155) AND STANDARD OF CARE THERAPIES OVERCOMES APOPTOTIC RESISTANCE IN GLIOBLASTOMA","volume":"26","author":"Fernandez","year":"2024","journal-title":"Neuro-Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-22-0786","article-title":"Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer","volume":"22","author":"Toader","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-754","article-title":"Unique pharmacological properties of dolaflexin-based ADCs- A controlled bystander effect","volume":"78","author":"Clardy","year":"2018","journal-title":"Cancer Research"},{"key":"B112","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-907","article-title":"XMT-1660, a B7-H4-targeted dolasynthen antibody-drug conjugate for the treatment of breast cancer","volume":"81","author":"Fessler","year":"2021","journal-title":"Cancer Research"},{"key":"B113","unstructured":"Mersana therapeutics announces positive initial clinical data from phase 1 clinical trial of emiltatug ledadotin (XMT-1660); initiation of expansion in triple negative breast cancer - mersana therapeutics"},{"key":"B114","unstructured":"XMT-1660 earns fast track designation for HER2\u2013low\/negative breast cancer\n          \n          2025"},{"key":"B115","unstructured":"Design and preclinical evaluation of a novel B7-H4-directed antibody-drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305 - pubMed"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.673","article-title":"606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced\/metastatic solid tumors","volume":"35","author":"Meric-Bernstam","year":"2024","journal-title":"Ann Oncol"},{"key":"B117","unstructured":"Novel B7-H4 targeted ADCs generate activity and show manageable safety profile in breast and other cancers\n          \n          2023"},{"key":"B118","unstructured":"GSK enters exclusive license agreement with Hansoh for HS-20093 | GSK\n          \n          2023"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.558","article-title":"381O First-in-human\/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors","volume":"34","author":"Wu","year":"2023","journal-title":"Ann Oncol"},{"key":"B120","unstructured":"GSK and Hansoh press on despite Pfizer\u2019s exit"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1158\/1538-7445.AM2024-1898","article-title":"Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers","volume":"84","author":"Fitzgerald","year":"2024","journal-title":"Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.1051","article-title":"1051 LNCB74 is a B7-H4 targeting antibody-drug-conjugate with a \u03b2-glucuronide linker-MMAE payload system to enhance the therapeutic index in B7-H4 expressing cancers","volume":"12","author":"Kahan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B123","volume-title":"DB-1312 by duality biologics (Shanghai) for esophageal cancer: likelihood of approval","year":"2024"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007572","article-title":"SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models","volume":"11","author":"Gray","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody\u2013drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-24-34","article-title":"B7 homolog 4 (B7-H4)-directed agents in oncology clinical trials: A review","volume":"8","author":"Phipps","year":"2025","journal-title":"J Immunother Precis Oncol"},{"key":"B127","article-title":"The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1079","article-title":"A B7-H4-targeting antibody-drug conjugate shows antitumor activity in PARPi and platinum-resistant cancers with B7-H4 expression","volume":"30","author":"Gitto","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"8514","DOI":"10.3390\/ijms23158514","article-title":"The significance of cell surface N-glycosylation for internalization and potency of cytotoxic conjugates targeting receptor tyrosine kinases","volume":"23","author":"Po\u017aniak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.11.020","article-title":"The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems","volume":"11","author":"Yang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae084","article-title":"sB7-H4 is a diagnostic biomarker in epithelial ovarian cancer and correlates to platinum resistance","volume":"219","author":"Zhou","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"B133","volume-title":"Novel Linker-Payload (SYNtecan ETM) based on Topoisomerase 1 Inhibitor Exatecan enables Potent ADCs with Promising","author":"Synaffix","year":"2020"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody\u2013exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody\u2013drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3390\/ijms18071434","article-title":"An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance","volume":"18","author":"Parker","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq064","article-title":"Homologous recombination in cancer development, treatment and development of drug resistance","volume":"31","author":"Helleday","year":"2010","journal-title":"Carcinogenesis"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.11.2.14623","article-title":"Cancer-stromal interactions: Role in cell survival, metabolism and drug sensitivity","volume":"11","author":"Zhang","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B139","doi-asserted-by":"publisher","first-page":"114890","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B140","doi-asserted-by":"publisher","first-page":"100039","DOI":"10.1016\/j.dmd.2025.100039","article-title":"Detection of antidrug antibodies against antibody-drug conjugates by solid-phase extraction with acid dissociation in cynomolgus monkey serum","volume":"53","author":"Chen","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax3160","article-title":"B7-H3\u00d74-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes","volume":"7","author":"You","year":"2021","journal-title":"Sci Adv"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.02.010","article-title":"An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers","volume":"31","author":"Zekri","year":"2023","journal-title":"Mol Ther"},{"key":"B143","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic viruses: priming time for cancer immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"B144","doi-asserted-by":"publisher","first-page":"TPS5611","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5611","article-title":"FORWARD II: A phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FR\u03b1)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer","volume":"34","author":"O\u2019Malley","year":"2016","journal-title":"J Clin Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","article-title":"Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI trial)","volume":"31","author":"Alqaisi","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:22:31Z","timestamp":1763619751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1683674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":145,"alternative-id":["10.3389\/fimmu.2025.1683674"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1683674","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1683674"}}